These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 9681985

  • 21. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates.
    Gouvea IE, Izidoro MA, Judice WA, Cezari MH, Caliendo G, Santagada V, dos Santos CN, Queiroz MH, Juliano MA, Young PR, Fairlie DP, Juliano L.
    Arch Biochem Biophys; 2007 Jan 15; 457(2):187-96. PubMed ID: 17184724
    [Abstract] [Full Text] [Related]

  • 22. Mutational analyses support a model for the HRV2 2A proteinase.
    Sommergruber W, Seipelt J, Fessl F, Skern T, Liebig HD, Casari G.
    Virology; 1997 Aug 04; 234(2):203-14. PubMed ID: 9268151
    [Abstract] [Full Text] [Related]

  • 23. Identification of a novel peptide substrate of HSV-1 protease using substrate phage display.
    O'Boyle DR, Pokornowski KA, McCann PJ, Weinheimer SP.
    Virology; 1997 Sep 29; 236(2):338-47. PubMed ID: 9325241
    [Abstract] [Full Text] [Related]

  • 24. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
    Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST.
    J Med Chem; 1998 Jul 16; 41(15):2819-34. PubMed ID: 9667971
    [Abstract] [Full Text] [Related]

  • 25. Blocking human enterovirus 71 replication by targeting viral 2A protease.
    Falah N, Montserret R, Lelogeais V, Schuffenecker I, Lina B, Cortay JC, Violot S.
    J Antimicrob Chemother; 2012 Dec 16; 67(12):2865-9. PubMed ID: 22865380
    [Abstract] [Full Text] [Related]

  • 26. Human cytomegalovirus protease complexes its substrate recognition sequences in an extended peptide conformation.
    LaPlante SR, Aubry N, Bonneau PR, Cameron DR, Lagacé L, Massariol MJ, Montpetit H, Plouffe C, Kawai SH, Fulton BD, Chen Z, Ni F.
    Biochemistry; 1998 Jul 07; 37(27):9793-801. PubMed ID: 9657693
    [Abstract] [Full Text] [Related]

  • 27. Ca(2+)-dependent protease I from Allomyces arbuscula.
    Ojha M.
    Biochem Biophys Res Commun; 1996 Jan 05; 218(1):22-9. PubMed ID: 8573135
    [Abstract] [Full Text] [Related]

  • 28. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
    Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST.
    J Med Chem; 1998 Jul 16; 41(15):2806-18. PubMed ID: 9667970
    [Abstract] [Full Text] [Related]

  • 29. Complete nucleotide sequence of the chiba virus genome and functional expression of the 3C-like protease in Escherichia coli.
    Someya Y, Takeda N, Miyamura T.
    Virology; 2000 Dec 20; 278(2):490-500. PubMed ID: 11118371
    [Abstract] [Full Text] [Related]

  • 30. Defining residues involved in human rhinovirus 2A proteinase substrate recognition.
    Sousa C, Schmid EM, Skern T.
    FEBS Lett; 2006 Oct 16; 580(24):5713-7. PubMed ID: 17007846
    [Abstract] [Full Text] [Related]

  • 31. Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate.
    Zunszain PA, Knox SR, Sweeney TR, Yang J, Roqué-Rosell N, Belsham GJ, Leatherbarrow RJ, Curry S.
    J Mol Biol; 2010 Jan 15; 395(2):375-89. PubMed ID: 19883658
    [Abstract] [Full Text] [Related]

  • 32. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
    Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW, Matthews DA, Patick AK.
    Antimicrob Agents Chemother; 2005 Feb 15; 49(2):619-26. PubMed ID: 15673742
    [Abstract] [Full Text] [Related]

  • 33. Development of an internally quenched fluorescent substrate for Escherichia coli leader peptidase.
    Zhong W, Benkovic SJ.
    Anal Biochem; 1998 Jan 01; 255(1):66-73. PubMed ID: 9448843
    [Abstract] [Full Text] [Related]

  • 34. Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies.
    Bonneau PR, Plouffe C, Pelletier A, Wernic D, Poupart MA.
    Anal Biochem; 1998 Jan 01; 255(1):59-65. PubMed ID: 9448842
    [Abstract] [Full Text] [Related]

  • 35. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
    Cameron CE, Grinde B, Jentoft J, Leis J, Weber IT, Copeland TD, Wlodawer A.
    J Biol Chem; 1992 Nov 25; 267(33):23735-41. PubMed ID: 1331099
    [Abstract] [Full Text] [Related]

  • 36. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
    Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL.
    J Med Chem; 1996 Dec 20; 39(26):5072-82. PubMed ID: 8978838
    [Abstract] [Full Text] [Related]

  • 37. Extended cleavage specificity of mMCP-1, the major mucosal mast cell protease in mouse-high specificity indicates high substrate selectivity.
    Andersson MK, Pemberton AD, Miller HR, Hellman L.
    Mol Immunol; 2008 May 20; 45(9):2548-58. PubMed ID: 18313755
    [Abstract] [Full Text] [Related]

  • 38. Identification of essential amino acid residues in the functional activity of poliovirus 2A protease.
    Yu SF, Lloyd RE.
    Virology; 1991 Jun 20; 182(2):615-25. PubMed ID: 1850921
    [Abstract] [Full Text] [Related]

  • 39. ADAM33 enzyme properties and substrate specificity.
    Zou J, Zhang R, Zhu F, Liu J, Madison V, Umland SP.
    Biochemistry; 2005 Mar 22; 44(11):4247-56. PubMed ID: 15766253
    [Abstract] [Full Text] [Related]

  • 40. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
    Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW, Ferre RA, Harr JE, Kosa MB, Worland ST.
    J Med Chem; 1999 Apr 08; 42(7):1213-24. PubMed ID: 10197965
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.